BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17593169)

  • 1. Sequential combination therapy for chronic hepatitis B: more challenges to be tackled.
    Tseng TC; Liu CJ; Kao JH
    Am J Gastroenterol; 2007 Jul; 102(7):1544; author reply 1545. PubMed ID: 17593169
    [No Abstract]   [Full Text] [Related]  

  • 2. [Focusing on the markers for monitoring and antiviral therapy in chronic hepatitis B virus infection].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2006 Nov; 14(11):836-7. PubMed ID: 17125613
    [No Abstract]   [Full Text] [Related]  

  • 3. [Managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Marcellin P; Lada O
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S5-8. PubMed ID: 17075487
    [No Abstract]   [Full Text] [Related]  

  • 4. Chronic hepatitis B: back to the future with HBsAg.
    Moucari R; Lada O; Marcellin P
    Expert Rev Anti Infect Ther; 2009 Aug; 7(6):633-6. PubMed ID: 19681689
    [No Abstract]   [Full Text] [Related]  

  • 5. [Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Bourlière M
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S34-6. PubMed ID: 17075495
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of children persistently infected with hepatitis B virus: seroconversion or suppression.
    Price N; Boxall EH
    J Antimicrob Chemother; 2007 Dec; 60(6):1189-92. PubMed ID: 17913721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Locarnini S; Warner N
    Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection.
    Hofmann WP; Soriano V; Zeuzem S
    Handb Exp Pharmacol; 2009; (189):321-46. PubMed ID: 19048206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Managing resistance to analogue antiviral drugs in a chronic compensated hepatitis B patient].
    Bronowicki JP; Barraud H; Couzigou P
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S17-9. PubMed ID: 17075490
    [No Abstract]   [Full Text] [Related]  

  • 10. Changing landscape of antiviral resistance management in chronic hepatitis B.
    Nguyen T; Locarnini S; Desmond P
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic hepatitis B infection in pregnancy illustrated by a case of successful treatment with entecavir.
    Kakogawa J; Sakurabashi A; Sadatsuki M; Gomibuchi H; Minoura S
    Arch Gynecol Obstet; 2011 Dec; 284(6):1595-6. PubMed ID: 21861151
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of sever polyneuropathy caused by hepatitis B virus with interferon alpha].
    Il'iankova AA; Krel' PE; Komiagin IuV; Il'ina NA
    Ter Arkh; 1998; 70(11):24-5. PubMed ID: 9949451
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic hepatitis B: preventing, detecting, and managing viral resistance.
    Keeffe EB; Dieterich DT; Pawlotsky JM; Benhamou Y
    Clin Gastroenterol Hepatol; 2008 Mar; 6(3):268-74. PubMed ID: 18328434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does hepatitis B surface antigen kinetics, including both decline and reaching a threshold, improve prediction of response?
    Wiegand J; Patel K; Tillmann HL
    Hepatology; 2009 Oct; 50(4):1314; author reply 1314. PubMed ID: 19676132
    [No Abstract]   [Full Text] [Related]  

  • 15. Revisiting the treatment recommendations for chronic hepatitis B.
    Chan HL
    Hepatology; 2009 Feb; 49(2):700; author reply 701-2. PubMed ID: 19177582
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiviral therapy of chronic hepatitis B: prevention of drug resistance.
    Fournier C; Zoulim F
    Clin Liver Dis; 2007 Nov; 11(4):869-92, ix. PubMed ID: 17981233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B?
    Alberti A
    Hepatology; 2003 Jul; 38(1):18-20. PubMed ID: 12829981
    [No Abstract]   [Full Text] [Related]  

  • 18. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.
    Zoulim F
    J Hepatol; 2005 Mar; 42(3):302-8. PubMed ID: 15710212
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis B virus carriers; natural course, diagnostic approach and treatment.
    Ranjan P; Aggarwal R
    Trop Gastroenterol; 2005; 26(2):58-65. PubMed ID: 16225046
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of chronic hepatitis B and the implications of viral resistance to therapy.
    Mauss S; Wedemeyer H
    Expert Rev Anti Infect Ther; 2008 Apr; 6(2):191-9. PubMed ID: 18380601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.